vs
Side-by-side financial comparison of Cellectis S.A. (CLLS) and Kymera Therapeutics, Inc. (KYMR). Click either name above to swap in a different company.
Kymera Therapeutics, Inc. is the larger business by last-quarter revenue ($11.5M vs $9.5M, roughly 1.2× Cellectis S.A.). Cellectis S.A. runs the higher net margin — -265.9% vs -667.6%, a 401.7% gap on every dollar of revenue. On growth, Cellectis S.A. posted the faster year-over-year revenue change (375.0% vs -55.3%). Cellectis S.A. produced more free cash flow last quarter ($27.6M vs $-60.6M).
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.
Kymera Therapeutics is a clinical-stage biopharmaceutical company specialized in developing innovative targeted protein degradation therapies. It advances a diversified pipeline of drug candidates targeting previously undruggable proteins to address unmet medical needs in oncology, autoimmune and inflammatory diseases worldwide.
CLLS vs KYMR — Head-to-Head
Income Statement — Q2 FY2024 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.5M | $11.5M |
| Net Profit | $-25.3M | $-76.6M |
| Gross Margin | — | — |
| Operating Margin | -181.1% | -736.8% |
| Net Margin | -265.9% | -667.6% |
| Revenue YoY | 375.0% | -55.3% |
| Net Profit YoY | -51.9% | -82.1% |
| EPS (diluted) | $-0.28 | $-0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | — | $11.5M | ||
| Q1 25 | — | $22.1M | ||
| Q4 24 | — | $7.4M | ||
| Q2 24 | $9.5M | $25.6M | ||
| Q1 24 | — | $10.3M | ||
| Q4 23 | — | $47.9M | ||
| Q3 23 | $1.6M | — | ||
| Q2 23 | $2.0M | $16.5M |
| Q2 25 | — | $-76.6M | ||
| Q1 25 | — | $-65.6M | ||
| Q4 24 | — | $-70.8M | ||
| Q2 24 | $-25.3M | $-42.1M | ||
| Q1 24 | — | $-48.6M | ||
| Q4 23 | — | $-14.4M | ||
| Q3 23 | $-17.5M | — | ||
| Q2 23 | $-16.6M | $-38.8M |
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | 97.3% | — |
| Q2 25 | — | -736.8% | ||
| Q1 25 | — | -336.8% | ||
| Q4 24 | — | -1092.2% | ||
| Q2 24 | -181.1% | -198.5% | ||
| Q1 24 | — | -562.2% | ||
| Q4 23 | — | -40.3% | ||
| Q3 23 | -1258.1% | — | ||
| Q2 23 | -1180.5% | -262.7% |
| Q2 25 | — | -667.6% | ||
| Q1 25 | — | -296.7% | ||
| Q4 24 | — | -956.9% | ||
| Q2 24 | -265.9% | -164.0% | ||
| Q1 24 | — | -472.0% | ||
| Q4 23 | — | -30.0% | ||
| Q3 23 | -1064.1% | — | ||
| Q2 23 | -831.6% | -235.0% |
| Q2 25 | — | $-0.95 | ||
| Q1 25 | — | $-0.82 | ||
| Q4 24 | — | $-0.89 | ||
| Q2 24 | $-0.28 | $-0.58 | ||
| Q1 24 | — | $-0.69 | ||
| Q4 23 | — | $-0.25 | ||
| Q3 23 | $-0.31 | — | ||
| Q2 23 | $-0.20 | $-0.67 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $149.0M | $335.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $148.6M | $971.5M |
| Total Assets | $407.1M | $1.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | $335.8M | ||
| Q1 25 | — | $90.0M | ||
| Q4 24 | — | $120.3M | ||
| Q2 24 | $149.0M | $67.6M | ||
| Q1 24 | — | $93.5M | ||
| Q4 23 | — | $110.0M | ||
| Q3 23 | — | — | ||
| Q2 23 | $84.4M | $52.4M |
| Q2 25 | — | $971.5M | ||
| Q1 25 | — | $786.2M | ||
| Q4 24 | — | $835.6M | ||
| Q2 24 | $148.6M | $684.9M | ||
| Q1 24 | — | $711.2M | ||
| Q4 23 | — | $395.0M | ||
| Q3 23 | $76.1M | — | ||
| Q2 23 | $96.6M | $435.4M |
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $918.3M | ||
| Q4 24 | — | $978.0M | ||
| Q2 24 | $407.1M | $826.0M | ||
| Q1 24 | — | $868.3M | ||
| Q4 23 | — | $575.8M | ||
| Q3 23 | $209.7M | — | ||
| Q2 23 | $227.7M | $581.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.9M | $-59.9M |
| Free Cash FlowOCF − Capex | $27.6M | $-60.6M |
| FCF MarginFCF / Revenue | 290.5% | -527.9% |
| Capex IntensityCapex / Revenue | 13.2% | 6.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-250.5M |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | $-59.9M | ||
| Q1 25 | — | $-79.2M | ||
| Q4 24 | — | $-61.8M | ||
| Q2 24 | $28.9M | $-42.9M | ||
| Q1 24 | — | $-39.6M | ||
| Q4 23 | — | $8.0M | ||
| Q3 23 | — | — | ||
| Q2 23 | $-47.4M | $-35.3M |
| Q2 25 | — | $-60.6M | ||
| Q1 25 | — | $-79.6M | ||
| Q4 24 | — | $-62.7M | ||
| Q2 24 | $27.6M | $-47.6M | ||
| Q1 24 | — | $-47.0M | ||
| Q4 23 | — | $-3.6M | ||
| Q3 23 | — | — | ||
| Q2 23 | $-47.9M | $-46.0M |
| Q2 25 | — | -527.9% | ||
| Q1 25 | — | -360.3% | ||
| Q4 24 | — | -848.3% | ||
| Q2 24 | 290.5% | -185.7% | ||
| Q1 24 | — | -456.8% | ||
| Q4 23 | — | -7.5% | ||
| Q3 23 | — | — | ||
| Q2 23 | -2391.4% | -278.7% |
| Q2 25 | — | 6.1% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | 12.7% | ||
| Q2 24 | 13.2% | 18.3% | ||
| Q1 24 | — | 72.0% | ||
| Q4 23 | — | 24.3% | ||
| Q3 23 | — | — | ||
| Q2 23 | 24.1% | 65.2% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
